Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2016-2023
The Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2016-2023 report provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty asset purchase deals.
The Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2016-2023 report provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty assets.
The report provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty assets.
The focus of the report is on partnerships for business, product, technology and royalty assets where partners have entered an agreement to dispose of or acquire said assets.
Companies may seek to dispose of an asset simply because it is surplus to requirements. Or it may seek to dispose of assets in order to raise funds to invest in others parts of its business. Or it may be due to a regulatory requirement to dispose of certain business or product assets as a result of a pending business merger in order to meet competition regulations.
The report provides access to asset purchase deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
The report focuses on four primary types of asset available for purchase:
- Business assets - the most common asset exchanging hands. Business assets are in the form of a business unit or subsidiary of a parent company. Common assets include territorial businesses or non-core businesses such as an OTC or diagnostics business, separate from the core business operations
- Product assets - in the form of marketed product, clinical phase development compound, or drug delivery-compound combination. These assets are commonly available as a result of a merger or change in direction of the selling company. The buyer acquires the asset for global or territorial exploitation. It is often the case that the acquiring company is normally a competitor to the seller, but in this situation the trade is of mutual benefit
- Royalty assets - where a specialist investment company acquires the rights to future royalty payments in return for payment of a lump sum payment to the licensor for the product
- Technology asset - where a buyer is acquiring a technology platform, research program, patent portfolio or other intellectual property asset. The acquisition is often due to the technology being surplus to a sellers interests, but may also be as a consequence of a sale of assets in advance of the seller entering liquidation
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of asset purchase deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual asset purchase contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of Asset Purchase dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in Asset Purchase as well as a discussion on the merits of the type of deal.
Chapter 3 provides an overview of the structure of Asset Purchase deals. The chapter includes numerous case studies to enable understanding of both pure Asset Purchase deals and multicomponent deals where Asset Purchase forms a part.
Chapter 4 provides a review of the leading Asset Purchase deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive listing of the top 25 most active Asset Purchase dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.
Chapter 6 provides a comprehensive and detailed review of Asset Purchase deals organized by company A-Z, therapy, technology and industry type signed and announced since 2016 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the Asset Purchase deal.
The appendices to the report includes a comprehensive listing of all Asset Purchase deals announced since 2016. Each listing is organized as an appendix by company A-Z, stage of development at signing, therapeutic area and industry type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.
The report also includes numerous table and figures that illustrate the trends and activities in Asset Purchase dealmaking since 2016.
In conclusion, this report provides everything a prospective dealmaker needs to know about Asset Purchase alliances.
Key benefits
Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2016-2023 provides the reader with the following key benefits:
- In-depth understanding of asset purchase deal trends since 2016
- Analysis of the structure of asset purchase agreements with real life case studies
- Comprehensive access to actual asset purchase deals entered into by the world’s biopharma companies
- Detailed access to actual asset purchase deals entered into by leading biopharma companies
- Insight into the terms included in a asset purchase agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scope
Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2016-2023 is intended to provide the reader with an in-depth understanding of the asset purchase trends and structure of deals entered into by leading biopharma companies worldwide.
Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2016-2023 includes:
- Trends in asset purchase dealmaking in the biopharma industry since 2016
- Analysis of asset purchase deal structure
- Case studies of real-life asset purchase deals
- Access to asset purchase deal records covering pharma, biotech, devices and diagnostics since 2016
- The leading asset purchase deals by value since 2016
- Most active asset purchase dealmakers since 2016
- The leading asset purchase partnering resources
In Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2016-2023, the available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Therapeutic area
- Technology type
Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
The Global Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2016-2023 report provides comprehensive access to available records for asset purchase deals, including contract documents where available. Analyzing actual contract agreements allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2016-2023 provides the reader with the following key benefits:
- In-depth understanding of asset purchase partnering deal trends since 2016
- Insight into the terms included in an asset purchase agreement, together with real world clause examples
- Identify leading asset purchase deals by value since 2016
- Identify the most active asset purchase dealmakers since 2016
- Full listing of asset purchase deals by company A-Z, deal value, phase of development, deal type, therapy and technology focus
- Comprehensive access to asset purchase deals entered into by the world’s biopharma companies, together with contract documents if available
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in Asset Purchase dealmaking
2.1. Introduction
2.2. Types of assets purchased
2.3. Trends in Asset Purchase deals since 2016
2.3.1. Asset Purchase dealmaking by year since 2016
2.3.2. Asset Purchase dealmaking by phase of development since 2016
2.3.3. Asset Purchase dealmaking by industry sector since 2016
2.3.4. Asset Purchase dealmaking by therapy area since 2016
2.3.5. Asset Purchase dealmaking by technology type since 2016
2.3.6. Asset Purchase dealmaking by most active company since 2016
2.4. Reasons for entering into asset purchase partnering deals
2.4.1. Business assets
2.4.2. Product assets
2.4.3. Royalty assets
2.4.4. Technology assets
2.5 The emergence of royalty asset purchase deals
2.5.1. Primary players in royalty asset purchase deals
2.5.2. The future of royalty asset purchase deals
2.6. The role of IP auction houses in asset purchase deals
2.6.1. Leading IP auction companies
2.7. The future of asset purchase agreements
Chapter 3 – Overview of Asset Purchase deal structure
3.1. Introduction
3.2. Asset purchase agreement structure
3.3. Example asset purchase agreements
3.3.1. Case study 1: Product asset
3.3.2. Case study 2: Business asset
3.4. Anatomy of a royalty asset purchase agreement
3.5. Example royalty asset purchase agreements
3.5.1. Case study 3: Royalty asset
Chapter 4 – Leading Asset Purchase deals
4.1. Introduction
4.2. Top Asset Purchase deals by value
Chapter 5 – Top 25 most active Asset Purchase dealmakers
5.1. Introduction
5.2. Top 25 most active Asset Purchase dealmakers
Chapter 6 – Asset Purchase deals including contracts directory
6.1. Introduction
6.2. Asset Purchase deals with contracts since 2016
Appendices
Appendix 1 – Asset Purchase dealmaking by companies A-Z
Appendix 2 – Asset Purchase dealmaking by industry sector
Appendix 3 – Asset Purchase dealmaking by stage of development
Appendix 4 – Asset Purchase dealmaking by therapy area
Appendix 5 – Asset Purchase dealmaking by technology type
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering
TABLE OF FIGURES
Figure 1: Definition of assets purchased
Figure 2: Trends in Asset Purchase deal announcements since 2016
Figure 3: Asset Purchase deals signed at each phase of development since 2016
Figure 4: Asset Purchase deals by industry sector since 2016
Figure 5: Asset Purchase deals by therapy area since 2016
Figure 6: Asset Purchase deals by technology type since 2016
Figure 7: Top 25 most active Asset Purchase dealmakers since 2016
Figure 8: Leading royalty asset investors
Figure 9: Leading IP auction companies
Figure 10: Components of the asset purchase deal structure
Figure 11: Components of the royalty asset purchase deal structure
Figure 12: Top Asset Purchase deals by value since 2016
Figure 13: Most active Asset Purchase dealmakers since 2016
Pricing options
- $3,995: single-user
- $5,745: multi-user
- $10,995: single site license
- $17,995: global site license
A full explanation of license type definitions can be found here.
Our guarantee
Price promise
We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.
Delivery Deadline
We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)
Latest report
If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.
Serious Security
We take your data and security seriously. See our privacy policy for details of how we manage your data.
All card payments are processed by SagePay.
Sales Support
If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.
- Total Trust
Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.
3CL Sciences, 3M, 3SBio, 4SC, 7D Surgical, 9 Meters Biopharma, A&E Medical, Abbott Laboratories, Abbvie, Abcam, AbCellera Biologics, ABEC, Acacia Research, Academy Medical, Acare Medical Science, Accord, Accuray, Acelity, Achaogen, AC Immune, Acino Pharma, Aclaris Therapeutics, Acorda Therapeutics, Acrotech Biopharma, Actavis (acquired by Watson), ACT Genomics, Acutus Medical, Adalvo, Adama, Adamis Pharmaceuticals, Adaptas Solutions, AdaptHealth, Additive Orthopaedics, Adello Biologics, Adenomed, Adhera Therapeutics, Adial Pharmaceuticals, ADMA Biologics, adMare BioInnovations, Admedus, Advanced Accelerator Applications, Advanced BioMatrix, Advanced Facialdontics, Advanced Neural Dynamics, Advanced Tear Diagnostics, Advanomics, AdvanSource Biomaterials, Advanz Pharma, Advent International, Advicenne, Aegis Sciences, Aerie Pharmaceuticals, Aesthetic Medical International, Aethon Therapeutics, AFFiRiS, AGC Asahi Glass, AGC Biologics, AgeX Therapeutics, Agilent Technologies, Agios Pharmaceuticals, Agrium, AiPing Pharmaceutical, Ajinomoto Bio-Pharma Services, Akida, Akkadeas Pharma, Akorn, Akoya Biosciences, Akrimax Pharmaceutical, Albumedix, Alcon Laboratories, Aleafia Health, Aleph Farms, Alere, Alexion Pharmaceuticals, Alexza Pharmaceuticals, Alfasigma, Alfred E. Mann Institute for Biomedical Engineering, AliveGen, ALK-Abello, Allegheny General Hospital, Allegis Pharmaceuticals, Allergan, Allergan Aesthetics, Alliance Pharma, Almac Group, Almirall, Alphagen Laboratories, Alphatec Spine, Alpine Immune Sciences, Altaris Capital Partners, Altarum Institute, Altavant Sciences, Altermune Technologies, Alvine Pharmaceuticals, Alvogen, Amarantus BioSciences, Amcor, American Regent, Amerigen Pharmaceuticals, AmerisourceBergen, Amgen, Amneal Pharmaceuticals, AMN Healthcare, Amplifybio, AmpliPhi Biosciences, Amplyx Pharmaceuticals, Ampronix, AMP Therapeutics, Amring Pharmaceuticals, Amygdala Neurosciences, Amyris, Angelini Pharma, Angiodynamics, ANI Pharmaceuticals, Antares Pharma, Antylia Scientific, Apollo Endosurgery, ApoPharma, Apotex, Applied Biology, Applied StemCell, Applied UV, Aptevo Therapeutics, APT Therapeutics, Aradigm, Aralez Pharmaceuticals, aratinga.bio SAS Group, Arcadia Biosciences, Arcadia Consumer Healthcare, argenx, Argon Medical Devices, ArisGlobal, Arivis, Arjo, Armetheon, Arranta Bio, Arrevus, Arteriocyte Medical Systems, Arthrosurface, Artizan Biosciences, Arysta LifeScience, Asana Biosciences, Ascension, Asklepios Biopharmaceutical, Aspargo Laboratories, Aspen Holding, Aspen Pharmacare Canada, Aspen Surgical Products, Assembly Biosciences, Assertio Therapeutics, Assisi Animal Health, Astellas Pharma, Astero Bio, AstraZeneca, Astrea Pharma, Atara Biotherapeutics, Athenex, Atlab Pharma, AtlantiCare, ATL Technology, Atnahs Pharma, ATP, Audax Private Equity, AuraGen Aesthetics, Auris Medical, Aurobindo Pharma, Aurora Cannabis, AuxoCell Laboratories, Avacta, Avadel Pharmaceuticals, Avantor, Avara Pharmaceutical Services, Avenue Therapeutics, Avid Bioservices, AXIM Biotechnologies, Aytu BioPharma, Azaya Therapeutics, Baktus, Banco de Sangre de Servicios Mutuos, Baptist Health Care, Baring Private Equity Asia, BarioSurg, Bausch Health Companies, Bavarian Nordic, Baxalta, Baxter International, Bayer, Bayer Animal Health, Bayer Healthcare, BBI Solutions, B Braun, Beartooth Therapeutics, Becton Dickinson, Beiersdorf, BeiGene, Beijing Genomics Institute (BGI), Bellicum Pharmaceuticals, Bellin Health, Bellus Health, Belyntic, Benuvia Therapeutics, Benvenue Medical, Berkeley Lights, BetterLife Pharma, BGI, Bial, Bigfoot Biomedical, Bio-Rad Laboratories, Bioanalytical Laboratory Services, BioAnalytical Systems, Bioceres, BioClinica, Biocon, BioCorRx, BioDelivery Sciences, Biodelta Nutraceuticals, Biodesix, BioDuro, Biogen, Bio Innovation Group, BioMedion, Biomerics, BioMotiv, Bionik Laboratories, BioNTech, BioNxt Solutions, BioPharma Services, BioReference Laboratories, BioSig Technologies, BioStem Technologies, Biostem US, BioTelemetry, Biotest Pharmaceuticals, Bioventus, BioVie, Blood and Plasma Research, Bluebird Bio, Bluelink Pharmaceuticals, Blumentech, BMG Pharmaceuticals, Boehringer Ingelheim, Boehringer Ingelheim Vetmedica, Bolt Biotherapeutics, Bone Therapeutics, Bora Pharmaceuticals, Boston Scientific, Boston Topicals, Bovie Medical, BoxView, Brainsway, Breckenbridge Pharmaceutical, BridgeBio Pharma, Bridgewest Group, Briggs Healthcare, Bristol-Myers Squibb, BroadOak Capital Partners, Bruker, BUCHI Labortechnik, Burgerhospital, BVI Medical, BWX Technologies, C2Dx, C3J Therapeutics, C4X Discovery, California Institute for Biomedical Research, Cambus Medical, Candela, Candel Therapeutics, Cannabis Manufacturer’s Guild, Cannara Biotech, Canon, Canon BioMedical, Cantel Medical, Caprion Proteomics, CaptoGlove, Cardinal Health, Cardiome Pharma, CardioSert, Cardiovascular Systems, Care Access Research, Carestream Health, Caret Pharma, Carterra, CASI Pharmaceuticals, CAS Medical Systems, Casper Pharma, Castle Biosciences, Catalent, Catalyst Biosciences, Catheter Research, CBL Group, Celator, Celdara Medical, Celgene, Celgene Cellular Therapeutics, Cellana, Cell Biosciences, Celling Biosciences, Cellistic, Cellmic, Celltrion, Celonic, Celsee, Celularity, Celyad, CEM, CEN Biotech, Centauri Therapeutics, Centene, Centinel Spine, Centre for Probe Development and Commercialization, Centrexion, Centurion Medical Products, Century Medical, Cequr, Cerebain Biotech, Cerecor, Cerner, Certara, Cerulean Pharma, Cerus, Change Healthcare, Charles River Laboratories, Cheplapharm Arzneimittel, Chiesi Farmaceutici, China Medical System, China Pharma Holdings, ChoiceSpine, Chroma Therapeutics, Chronos Therapeutics, Cilag AG, Cinven, Cipher Pharmaceuticals, Cipla, Circadian Wellness, Cirrus Dx, Cirrus Pharmaceuticals, CJ CheilJedang, Clarus Therapeutics, Clayton Dubilier & Rice, Cleveland Clinic, Clinique Les Trois Soleils, Clovis Oncology, Co-Diagnostics, Co.Don, Codan Triplus, Codiak BioSciences, Coeptis Pharmaceuticals, College Park Industries, Collegium Pharmaceuticals, Colorcon, Concert Pharmaceuticals, Concord Biosciences, Confluent Medical Technologies, Contura, ConvaTec, Conventus Orthopaedics, Cook Medical, Cooper-Vemedia, Cooper Companies, Cooper Surgical, Coram, Cord Blood Registry, Corden Pharma, Cordis, CorDynamics, Corin, Corium International, CorMatrix Cardiovascular, Corning, Coronado Biosciences, Corza Health, Cosmed Group, Covance, Covestro, Covetrus, Covis Pharmaceutical, Covistat, Cranford Pharmaceuticals, C R Bard, CR Kennedy & Company, CROMA Pharma, CROS NT, Crown Bioscience, Crown Laboratories, Cryolife, CSPC Pharmaceutical Group, CTD Holdings, CTI BioPharma, Cubex, Cullinan Oncology, Cumberland Emerging Technologies, Cumberland Pharmaceuticals, CURE Pharmaceutical, Curi Bio, Custopharm, CVC Capital Partners, Cyanotech, Cybin, CYduct Diagnostics, Cynata Therapeutics, Cypralis, Cyprium Therapeutics, Cytek Biosciences, Cytonet, Cytori Therapeutics, Cyxone, Daiichi Sankyo, Danaher, Daniel Alain Life Science, Dartmouth College, Dascena, DAS Therapeutics, Daylight Medical, Dechra Pharmaceuticals, DeciBio Consulting, Delpharm, Delta, Denovo Biopharma, Dentsply International, Department of Veterans Affairs, DePuy, DermaPort, Dermira, DermOQ, Desma HC, DeuteRx, DiamiR, DiaSorin, Digirad, Dilon Diagnostics, Discovery Life Sciences, Distal Access, Diversey Care, DJO Surgical, Dong-A Pharmaceutical, DOSE Medical, Dr. Reddy's Laboratories, DS Healthcare, DSM, DSM Nutritional Products, DT MedTech, Dualogics, Ducere Pharma, Dune Medical Devices, DuPont, Duran Group, Durect, Dutch Emotional Brain, EaglePicher Technologies, Eckert & Ziegler, Edan Diagnostics, Eddingpharm, Eden Biologics, EdiGene, Edison Nation, Editas Medicine, Edogawa Hospital, Edwards Lifesciences, Egalet, Ehave, Eiger BioPharmaceuticals, E Ink, Elanco, Elanix Biotechnologies, Electrical Geodesics, Elekta, Elektron Eye Technology, Elencee, Eleven Biotherapeutics, Eli Lilly, ELT Sight, Eluminex Biosciences, Ember Therapeutics, Embolitech, Emerald Health Therapeutics, Emergent BioSolutions, Emmes, Empyrean Medical Systems, EnBiotix, Encore Medical, Endonovo Therapeutics, Endo Ventures, Enko, EnteroMedics, Entheon Biomedical, Envigo, Environmental Tectonics Corporation, Envisia Therapeutics, Envista, EnWave, Enzyvant Science, EpiBiome, EPI Health, Equillium, ERT, Escape Therapeutics, Espada Dermatology, Essential Pharmaceuticals, Ethicon Endo-Surgery, Ethismos Research, Eton Pharmaceuticals, EUSA Pharma, Euthymics Bioscience, Evah, Evonik Industries, Evotec, Exactech, Exelixis, Expedeon, Exuma Biotech, Eyevance, Fairlong Capital, Ferring Pharmaceuticals, Finch Therapeutics, Firsthand Technology, Flagship Biosciences, Flamma, Flexion Therapeutics, Flexpoint Sensor Systems, FMC, Focus Laboratories, FORMA Therapeutics, Fortive, Fosun Pharmaceutical, Fougera Pharmaceuticals, Foundation Consumer Healthcare, Fox Chase Chemical Diversity Center, Frankfurt University Hospital, Freedom Innovations, Freedom Meditech, Fresenius Kabi Pharmaceuticals, Fresenius Medical Care, Freudenberg Medical, Freya Pharma Solutions, Fujifilm, Fujifilm Diosynth Biotechnologies, Fusion Pharmaceuticals, G&W Laboratories, Galderma, Galen, Galgo Medical, GamaMabs Pharma, Gamma Medica, Gardia Medical, GC Pharma, GE Healthcare, Gem Pharma, GenePOC, GeneQuine Biotherapeutics, Genesis Biotechnology Group, Genesis MedTech, Genetrix, GeneWorks, Genomic Health, Genovac, George Clinical, Gerresheimer, Gesynta Pharma, Gilead Sciences, Ginkgo BioWorks, GI Reviewers, Givaudan, Glaukos, GlaxoSmithKline, GL Capital Group, Glenmark Pharmaceuticals, Global Medical Solutions, Globus Medical, Glycotope Biotechnology, Gowan Crop Protection, GPI Group, GrandOmics Biosciences, Great Belief International, Greenlight Biosciences, Greenteaspoon, Grifols, Grunenthal, GT Biopharma, Guangdong Lewwin Pharmaceutical Research Institute, Guerbet, Gurnet Point Capital, GVS, Gyrus Capital, H-CYTE, H2-Pharma, Hackensack University Medical Center, Haemonetics, Halo Labs, Halyard Health, Havn Life Sciences, HCA Healthcare, Healeon Medical, Healion Bio, Healiva, Health Outcomes Sciences, HealthTrackRx, HeavenlyRx, heliosDX, Hellman & Friedman, Henry Ford Health System, Henry Schein, Heritage Group, Heritage Pharmaceuticals, Heska, High Ridge Brands, Hikma Pharmaceuticals, Hill-Rom, Hillstream BioPharma, HLS Therapeutics, HMNRTH, Hoffmann La Roche, Holmdel Pharmaceuticals, Hologic, Horizon Discovery, HOYA Vision Care, HS Pharmaceuticals, Hubertus Apotheke am Salzufer, Hubro Therapeutics, Huifeng Bio-Pharmaceutical Technology, Humanetics, Humanitas University, Human Longevity, Huntsman, Hutchinson Technology, Hutchison China MediTech, Hypera Pharma, i2 Pharmaceuticals, iAnthus Capital, IBA, IBA Molecular Imaging, iCAD, Icagen, ICU Medical, IDEAYA Biosciences, IEH Laboratories & Consulting Group, IFM Therapeutics, Igenica, IlmixGroup, Imagin Medical, Immuneed, ImmuneHealth, Immune Therapeutics, ImmunGene, Immunic, ImmunityBio, ImmunoCellular Therapeutics, ImmunogenX, ImmunoTek Bio Centers, Impax Laboratories, Implant Sciences, Inceptor Bio, Indivior, Indivumed, Infab, InfusAID, InfuSystem Holdings, Initiator Pharma, Innospec, INNOVAMEDICA, Innovation Skane, Innovus Pharmaceuticals, iNova Pharmaceuticals, Inovet, Inozyme Pharma, In Silico Biosciences, Inspirata, Instem, Institut du Cancer Courlancy, Insulet, Intas Pharmaceuticals, Intavis Bioanalytical Instruments, Integra LifeSciences, Integrated DNA Technologies, Integrated Proteomics Applications, Integrative Medicine, IntegriChain, International Biomedical, International Isotopes, International Process Plants, International Vitamin, Interpace BioPharma, Interventional Spine, IntraFuse, Invekra, Invitae, Ionic Brands, Ipsen, iQ Group, IQVIA, Iridex, Iroko Pharmaceuticals, Irras, IRX Therapeutics, Isologic Innovative Radiopharmaceuticals, IsoPlexis, Isto Technology, Itamar Medical, Iuvo BioScience, J. Morita, Jackson Laboratory, Janssen Biotech, Janssen Diagnostics, Janssen Pharmaceutica NV, Janssen Sciences, Japan Tobacco, Jazz Pharmaceuticals, Johnson & Johnson, John Wiley and Sons, Journey Medical, JT Pharmaceuticals, Juvise Pharmaceuticals, KabaFusion, Kala Pharmaceuticals, Kamada, Kancera, Kane Biotech, Kantar Health, karmadata, Karo Pharma, Karyopharm Therapeutics, Kashiv BioSciences, KD Pharma, KEDPlasma, Kedrion, KemPharm, Kemwell BioPharma, Kensing, Keyrus Biopharma, Kimberly-Clark, Kindred Bio, Kindstar Globalgene Technology, Kiniksa Pharmaceuticals, Kite Pharma, KNOW Bio, Kohlberg Kravis Roberts (KKR), Kolltan Pharmaceuticals, Korsch, Kramer Laboratories, Kronos Bio, Kuros Biosciences, Kyocera, L'Oreal, L-3 Communications, L3Harris Technologies, Laboratoires DELBERT, Laboratoire Serb, Laboratoires Thea, Laboratorio Medinfar, Laboratorios Rubio, Laboratory Corporation of America, Labworks, La Jolla Institute for Allergy & Immunology, Lannett, Lantheus Holding, Lanxess, Lanzhou Ion Therapy, Laurel Venture Capital, Lautus Pharmaceuticals, LeMaitre Vascular, LensAR, LEO Pharma, Les Laboratoires Servier, Lexicon Pharmaceuticals, LGC, LGM Pharma, LI-COR Biosciences, LIC Automation, Lifecode, Lifecycle Biotechnologies, Ligand Pharmaceuticals, Lighthouse Pharmaceuticals, Liminal BioSciences, Lincotek Medical, LindaCare, Lineage Cell Therapeutics, LineaRx, Link Fund Solutions, LivaNova, Livestock Improvement, LivNao Technologies, Lobe Sciences, Lobesity Pharma, Locus Biosciences, Longitude Capital, Lonza, Lorem Vascular, LOTTE, Lotus Biotechnology Development, Loxo Oncology, LSNE Contract Manufacturing, LTL Pharma, Luitpold Pharmaceuticals, Lumenis, LumenR, Luminera, Luminex, LumiThera, Lumos Pharma, Luye Pharma Group, MAB Discovery, MabVax Therapeutics, Macrogen, Macrogenics, MacuLogix, Magstim, Mainz Biomed, Malin, Mallinckrodt Pharmaceuticals, Mandos, MannKind Biopharmaceuticals, Maravai LifeSciences, Marina Biotech, Marin Community Foundation, Marinus Pharmaceuticals, Marizyme, Masimo, Mati Therapeutics, Matrivax, Matrox, Maxima Pharmaceuticals, Mayne Pharma, Mayo Clinic, MC10, McKesson, MD Anderson Cancer Center, MDxHealth, MEDCIS Pathlabs, Medeon Biodesign, MedGenome, Medical Developments International, Medical Products Laboratories, Medical University of Vienna, Medican Enterprises, Medidata Solutions, MediGene, Medigus, Medimetrics, MediPines, Medisca, Medivir, Medline Industries, Mednax, MedPlast, MedQualis, Medtronic, Megadalton Solutions, Melinta Therapeutics, Menarini, Menarini Asia-Pacific, Mentice, Merck and Co, Merck Animal Health, Merck KGaA, Merck Sharpe & Dohme, Meridian Bioscience, Merit Medical Systems, Merrimack Pharmaceuticals, Merus Labs International, Merz, Mesa Laboratories, METabolic EXplorer, Metabolix, Metrion Biosciences, Microba Life Sciences, Microbot Medical, Micro Hydraulics, Microlin Bio, MicroPort Scientific, Microsoft, MiGenTra, Mikart, MilliporeSigma, Minapharm, Mind Medicine, Minerva Surgical, Miravo Healthcare, Mirum Pharmaceuticals, Mitralign, Mitsubishi Chemical, MLase, MMT Technologies, Moberg Pharma, Modernizing Medicine, MolecuLight, Molnlycke Health Care, Molplex Pharmaceuticals, Molteni Farmaceutici, Momentis Surgical, Monopar Therapeutics, Montagu Private Equity, Mountain Valley MD, Mount Sinai Health System, MSC, MSD Animal Health, Mucokinetica, Myconic Capital, Mylan Laboratories, Mylan Pharmaceuticals, Myonex, Myovant Sciences, Myriad Genetics, Naari Pharma, Nanion, NanoProteagen, Nanotherapeutics, NantHealth, Natera, National Cancer Center, National Resilience, Natus Medical, NEC OncoImmunity, NEMO Health, Neogen, Neograft Technologies, Neosurgical, NeoSync, Neovasc, Neptune Wellness Solutions, Nestle, Nestle Health Science, NeuBase Therapeutics, Neuraxpharm, NeurMedix, NeuroBo Pharmaceuticals, NeuroOne, Neuropathix, NeuroSearch, Nevakar, Newport Research, Nexelis, Nexeon MedSystems, Nexgen Pharma, Nextmune, Nido Surgical, Nines, Nitiloop, NLC Pharma, NLT Spine, NOHO, Noramco, Nora Pharma, Nordion, Norgine, North American Partners in Anesthesia, North American Science Associates, Northwestern Memorial Hospital, Nostrum Pharmaceuticals, Novan Therapeutics, Novartis, Novarum, Novasep, Novelion Therapeutics, Noventia Pharma, NovImmune, Novogene, Novogy, Novolytics, Novo Nordisk, NOW Diagnostics, Nuclera, Nutriband, Nuvisan Pharma Services, NYU Langone Medical Center, Oakrum Pharma, OBI Pharma, ObsEva, Occlugel, Octant, Ocugen, Oculus Innovative Sciences, Olon, Omeros, Omnia Biologics, Oncimmune, Oncodesign, Oncologie, Oncopeptides, OncoQuest, OncoVision, Onkos Surgical, Ono Pharmaceutical, OpenBiome, OpenGate Capital, Oragenics, Orchard Therapeutics, Orexigen Therapeutics, Orexo, Orgenesis, Orifarm, Orion, Orphazyme, Orsenix, Orthofix Medical, OsteoCentric Technologies, Osteomed, Otifex Therapeutics, Otonomy, Otsuka America Pharmaceutical, Ottawa Hospital Research Institute, Oxford Instruments, OxyPharma, P2P Staffing, P3 Health, Pacific Biosciences, PACT Pharma, Padagis, Palisade Bio, PanGenomic Health, PanTheryx, Paragon 28, Parexel, Partner Therapeutics, Pascal Biosciences, Patient Genesis, Paulaur Corporation, PEAR Therapeutics, Performance Health, PeriGen, Periphagen Holdings, PerkinElmer, Perkins Healthcare Technologies, Pernix Therapeutics, Perrigo, Perry Baromedical, PetIQ, PetLife Pharmaceuticals, Pfizer, Pharmaceutical Associates, Pharmacia, Pharmacyclics, PharmaEngine, PharmaLogic, Pharma Logistics, Pharmapar, Pharmaron, PharmaTher, PhaseBio Pharmaceuticals, PHC Holdings, Phenomics Health, PhotoMedex, Photonamic GmbH, Piedmont Pharmaceuticals, Pierre Fabre, Piramal, Piramal Healthcare, PKG, Plus Therapeutics, PMC Group, PM Clinical, Pocono Coated Products, Polypeptide Laboratory, Pragma Pharmaceuticals, Praha Vaccines, Precera Bioscience, Precisa Medical Instruments, Precision Biomonitoring, Precision Eye Services, Premier Inc, PrepMD RMS, Presbia, Pressure BioSciences, Prestige Brands, Prestige Consumer Healthcare, Prevent Biometrics, Primavera Capital Group, Primex Pharmaceuticals, Prisma Health, ProBioGen, ProBiora Health, Procter & Gamble, Profound Medical, Progenics Pharmaceuticals, Progenity, Proliant Health and Biologicals, Promethera Biosciences, Promius Pharma, Propel Labs, Propel Orthodontics, Prophase Labs, Proteor, Proteus Digital Health, Prothena Biosciences, Provention Bio, Psomagen, Pulse Biosciences, Pulssar Technologies, Puration, PureTech Health, Purnovate, Q2 Solutions, Qiagen, QT Vascular, Quadrifolia Management, Quest Diagnostics, Quidel, Quince Therapeutics, Quintiles IMS Holdings, R1 RCM, Radius Health, Rafarma Pharmaceuticals, Rakuten Medical, Ra Medical Systems, RaNA Therapeutics, Randob Labs, Rasna Therapeutics, Rayner Surgical, RaySearch Laboratories, Real Brands, Realm Therapeutics, Recipharm, Reckitt Benckiser, Recordati, Redx Pharma, ReGen Scientific, ReLive Biotechnologies, Remedy Pharmaceuticals, Renaissance Acquisition Holdings, Renovis, ReShape Lifesciences, ReShape Medical, Resilience, Resonetics, Retinagenix, RetroSense Therapeutics, Revive Therapeutics, Revogenex, Revo Squared, Rexgenero, Rex Medical, Rio Grande Neurosciences, Roam Analytics, Roche, Rodo Medical, Rohner, Roivant Sciences, Rosemont Pharmaceuticals, RoundTable Healthcare Partners, RoverMed BioSciences, Roxall, Royal Philips Electronics, RTI Surgical, Rubius Therapeutics, Rumpus Therapeutics, Safegard Medical, SafeWire, Saint-Gobain Performance Plastics, Saladax Biomedical, Salarius Pharmaceuticals, Salvin Dental Specialties, Sample6, Samsung Bioepis, Samsung Biologics, Sandoz, Saniona, Sanofi, Sanuwave Health, Saol Therapeutics, Sarnova, Sartorius Stedim Biotech, Savant HWP, Sawai Pharmaceuticals, Scapa Healthcare, Schwazze, Science 37, Scion Solutions, Scynexis, Sea Lane Biotechnologies, Searchlight Pharma, SeaSpine, Sebacia, Sectra, SeD Biomedical, Seelos Therapeutics, Selenity Pharmaceuticals, Seneca, Sensus Healthcare, Sentynl Therapeutics, SERB Pharmaceuticals, Serenity Bioworks, Seventh Wave, Shandong Boan Biological Technology, Shandong Xinhua Pharmaceutical, Shardna, Sharp Fluidics, Sharps Technology, Shionogi, Shire Human Genetic Therapies, Shire Laboratories, Shire Pharmaceuticals, Shoreline Biosciences, Sibannac, Sienna Biopharmaceuticals, Sientra, Sierra Oncology, Sigma Analytical Services, Signati Medical, Signet Healthcare Partneers, Simplyfeye, Sinclair Research, Singulex, SI Pharmaceuticals, Sirio Pharma, Sirona Medical, SIT Laboratorio Farmaceutico, SK Capital Partners, Skin Products, Sloan Pharma, SmartBreast, Smith & Nephew, Smithers Avanza, Smiths Medical, Social Reality, SOCPRA Sciences Sante et Humaines, Sofregen Medical, Sol-Gel, Solulink, Solvay, Sonic Healthcare, Sorrento Therapeutics, Sorse Technology, Southern Research Institute, Spacelabs Healthcare, Spark Therapeutics, Spartan Medical, Spear Pharmaceuticals, Spectrum Pharmaceuticals, Spinal Elements, Sproutly, Spry Health, SQI Diagnostics, STADA Arzneimittel, Stanford Health Care, Starboard Medical, Stark Investments, Starpharma, Steeper Group, Stellar Biotechnologies, StemBioSys, Stericycle, Sterigenics, St Jude Medical, Strand Life Sciences, STRATA Skin Sciences, Straumann, Strides Arcolab, Strongbridge Biopharma, Stryker, SugarLeaf Labs, Sumitomo Dainippon Pharma, Sumitovant Biopharma, Summa Health System, Sun Pharmaceutical, Sunshine Biopharma, Sunstar Suisse, Super-T Cell Cancer, SuperiorVAS, Supernus Pharmaceuticals, Surgalign, SurgCenter Development, Surgical Specialties, SurModics, Swedish Orphan Biovitrum, Symmetry Surgical, Symplmed Pharmaceuticals, Synaptive Medical, Synergetics, Synergy Pharmaceuticals, SynGen, Syngene International, Synthetic Genomics, Syros Pharmaceuticals, Systagenix Wound Management, Tabuk Pharmaceutical, Tabula Rasa HealthCare, Taiho, Taisho Pharmaceutical, Takeda Pharmaceutical, Tamir Biotechnology, Targacept, Targovax, Taro Pharmaceuticals, Tasly Pharmaceuticals, Tec-Pharm, Tecan, Teijin Nakashima Medical, TekCyte, Tekni-Plex, Teleflex, Teligent, Telix Pharmaceuticals, Tenet Healthcare, Terran Biosciences, TerSera Therapeutics, Terumo, Tesaro, Tesla Digital, TetraLogic Pharmaceuticals, Teva Pharmaceutical Industries, Teva Pharmaceuticals USA, The DNA Company, The Green Organic Dutchman Holdings, The Medicines Company, Therabody, Theraclion, Theragene Pharmaceuticals, Theragenics, Therakine, TheraLight, Therapeia, Therapeutic Solutions International, Therapix Bio, Therapure Biopharma, Theravance Biopharma, Theravant, ThermiGen, Thermo Fisher Scientific, ThermoGenesis, THINK Surgical, Threshold Pharmaceuticals, Tibet Rhodiola Pharmaceutical Holding Co, TiGenix, Tilray, Tissue Regeneration Systems, Titan Pharmaceuticals, Tiziana Life Sciences, TKL Research, Tocagen, Todos Medical, Tolmar, Tonbo Biosciences, TONIX Pharmaceuticals, Topcon, Torrent Pharmaceuticals, Toshiba, Toxikon, Transcatheter Technologies, Transcend Biodynamics, TransEnterix, Transgene, Transgene Tasly Biopharmaceutical, Translate Bio, TrialSpark, Trigemina, TriLink BioTechnologies, Trinity Medical Devices, TriReme Medical, TriRx Pharmaceutical Services, Trividia Health, Trod Medical, Turing Pharmaceuticals, Twist Bioscience, uBiome, UCB, Ultimovacs, Ultra Scientific, Unichem, Unicycive Therapeutics, Unilever, University of Guelph, University of Helsinki, University of Oklahoma, University of Pittsburgh Medical Center, University of Texas, University of Washington, Upsher-Smith, Urgo Laboratories, Urovant Sciences, US Compounding, US WorldMeds, Valeant Pharmaceuticals, Valo Health, Valo Therapeutics, Vance Street Capital, Vantage Endoscopy, Varex Imaging, Varian Medical Systems, Vascular Graft Solutions, Vault Health, Vaximm, Vaxxel, VBL Therapeutics, Vector Oncology, Velocity Clinical Research, Vention Medical, Venus Medtech, Vera Therapeutics, Verios Agro, Vertex Pharmaceuticals, Vetoquinol, Viamet Pharmaceuticals, Viatris, Vibliome Therapeutics, ViewPoint Therapeutics, ViewRay, Vifor Pharma, Vigene Biosciences, Vimian Group, Viracta Therapeutics, Virbac, Virox Technologies, Viscogliosi Brothers, Visus Therapeutics, Vital Therapies, Vitatex, Vitesse Biologics, Viveca Biomed, Vivos Therapeutics, Vtesse, VuCOMP, Vyera Pharmaceuticals, VYNE Therapeutics, W.R.Grace, Walgreens, Walter Reed Army Institute of Research, Warp Drive Bio, Wasas, Waters Corporation, Wavelength Pharmaceuticals, Wave Neuroscience, WavePoint Medical, Webster Equity Partners, Wellspring Ophthalmics, Wenzel Spine, WIRB-Copernicus Group, Wittenstein, Wockhardt, Wright Medical, Wuhan Humanwell, WuXi Biologics, Wuxi STA, X-chem, X2 Biosystems, Xbiome, XBiotech, Xcelerate Solutions, Xoma, Xtant Medical, Yantai Dongcheng Biochemicals, York Instruments, Young Innovations, Yumanity Therapeutics, ZAP Surgical Systems, Zealand Pharma, Zebra technologies, Zentiva, Zomedica, Zymergen, ZYUS Life Sciences
Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.
The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant
Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.
